This section highlights FDA-related milestones and regulatory updates for drugs developed by Kailera Therapeutics (KLRA).
Over the past two years, Kailera Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
ribupatide and KAI-9531. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Ribupatide FDA Regulatory Events
Ribupatide is a drug developed by Kailera Therapeutics for the following indication: GLP-1/GIP/glucagon receptor tri-agonist in obesity.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- ribupatide
- Announced Date:
- November 10, 2026
- Indication:
- GLP-1/GIP/glucagon receptor tri-agonist in obesity.
Announcement
- Kailera Therapeutics, Inc announced that new clinical and real-world research will be presented at ObesityWeek 2026, taking place November 14-17 in Washington, D.C. .
Read Announcement- Drug:
- ribupatide
- Announced Date:
- October 1, 2026
- Indication:
- GLP-1/GIP/glucagon receptor tri-agonist in obesity.
Announcement
Kailera Therapeutics, Inc. announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD).
AI Summary
Kailera Therapeutics presented Phase 1 findings for ribupatide injection at the 62nd Annual Meeting of the European Association for the Study of Diabetes. Ribupatide is a once-weekly GLP-1/GIP receptor dual agonist being studied for obesity and is now in global Phase 3 trials. The new study examined whether the injection site affected how much medicine entered the bloodstream and its safety.
The randomized crossover trial included 51 adults with overweight or obesity. Each participant received one 2 mg dose in the abdomen, upper arm, and thigh during three separate 29-day periods. Drug exposure after injections in the arm or thigh was similar to exposure after abdominal injections, suggesting both are alternative sites. Ribupatide was generally well tolerated at all three sites, and researchers found no new safety concerns. Most reported side effects were mild and related to the digestive system. The results support flexibility in where patients may inject the drug, but the study assessed only single doses in a small group.
Read Announcement
KAI-9531 FDA Regulatory Events
KAI-9531 is a drug developed by Kailera Therapeutics for the following indication: for the treatment of people living with obesity or overweight.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- KAI-9531
- Announced Date:
- September 30, 2026
- Indication:
- for the treatment of people living with obesity or overweight.
Announcement
Kailera Therapeutics, Inc. announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight.
AI Summary
Kailera Therapeutics has completed enrollment in its global Phase 3 KaiNETIC program, which is testing ribupatide injection, also called KAI-9531, as a once-weekly treatment for adults with obesity or overweight. The investigational medicine is a dual GLP-1/GIP receptor agonist. The three trials enrolled about 4,900 participants at more than 200 sites in 11 countries.
KaiNETIC-1 and KaiNETIC-2 will assess several ribupatide doses against placebo. KaiNETIC-1 includes adults with obesity or overweight and a related health condition, while KaiNETIC-2 focuses on people with type 2 diabetes. KaiNETIC-3 is studying adults with a BMI of 35 kg/m² or higher, comparing ribupatide with placebo and semaglutide. This group reflects Kailera’s goal of addressing the need for greater weight loss, especially for people with higher BMI. Treatment lasts 76 weeks. Topline results from all three trials are expected in mid-2028.
Read Announcement